Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Evolus Q3 revenue rises 13% on toxin and HA gel growth

By Reuters News


Overview

  • US injectable aesthetics firm's Q3 revenue rose 13% yr/yr, driven by toxin and HA gel growth

  • Company posted fourth straight quarter of positive adjusted EBITDA, reflecting improved operating leverage

  • Evolus reaffirmed 2026 revenue and adjusted gross margin guidance, citing confidence in outlook


Outlook

  • Evolus reaffirms 2026 net revenue guidance of $330 mln to $337 mln

  • Company reaffirms 2026 adjusted gross profit margin guidance of 67.0% to 67.5%

  • Evolus updates 2026 non-GAAP operating expense guidance to $210 mln to $213 mln


Result Drivers

  • TOXIN REVENUE GROWTH - Co said global toxin revenue rose about 11% yr/yr in Q3, supporting overall revenue growth

  • HA GEL PORTFOLIO - Revenue from injectable hyaluronic acid (HA) gels grew nearly 40% yr/yr in Q3, with the portfolio gaining market share

  • COMMERCIAL EXECUTION - Co attributed results to healthy consumer demand, increased customer penetration, strong reorder behavior, and scalability of its digital platform


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Product Revenue

$77.21 mln

Q3 Net Loss

$12.52 mln

Q3 Gross Margin

65.00%

Q3 Adjusted Gross Margin

66.10%

Q3 Gross Profit

$50.69 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Evolus Inc is $13.00, about 76.4% above its November 3 closing price of $7.37

  • The stock recently traded at 42 times the next 12-month earnings vs. a P/E of 61 three months ago


Reuters Recommended Reads

  • Nov 4 - Lifecore Biomedical Q3 revenue misses estimates as CDMO, HA sales decline

  • Nov 3 - Madrigal Q3 Rezdiffra sales jump on strong demand, posts first profit

  • Nov 2 - Travere Q3 product sales nearly double on FILSPARI growth


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.